Next-Generation Ophthalmic Surgical Platform Now Available
Across Greater Europe
LAVAL, Quebec, Jan. 8, 2018 /CNW/ -- Bausch + Lomb, a
leading global eye health company and wholly owned subsidiary of
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:
VRX) ("Valeant"), today announced that it has received CE Mark from
the European Commission for the Stellaris Elite™ Vision
Enhancement System, the company's next generation ophthalmic
surgical platform, which includes Vitesse™, the first and only
hypersonic, open-port vitrectomy system.
The Stellaris Elite platform is now available throughout greater
Europe, including the 28 countries
of the European Union, Iceland,
Liechtenstein, Norway and Switzerland.
"We're pleased to bring the Stellaris Elite Vision Enhancement
System, including the cutting-edge Vitesse technology, to the
greater European market," said Joseph C.
Papa, chairman and CEO, Valeant. "Because this surgical
platform offers the opportunity to continuously add innovative
upgrades and enhancements, it enables surgeons to customize their
systems and expand their capabilities as their needs evolve without
having to invest in a new surgical system."
Already available in the United
States, the Stellaris Elite Vision Enhancement System is the
first phacoemulsification platform to offer Adaptive Fluidics™,
which combines precise aspiration control with predictive infusion
management to create a highly responsive and controlled surgical
environment for efficient lens removal.* As part of the platform's
vitreoretinal capabilities, the Vitesse hypersonic vitrectomy
system uses a novel, single-needle design and continuously
open-port system that represents the first major advancement in
vitreous removal in 40 years. Vitesse will be available exclusively
on the Stellaris Elite platform.
About Bausch + Lomb
Bausch + Lomb, a Valeant
Pharmaceuticals International, Inc. company, is a leading global
eye health organization that is solely focused on protecting,
enhancing and restoring people's eyesight. Its core businesses
include over-the-counter supplements, eye care products, ophthalmic
pharmaceuticals, contact lenses, lens care products, ophthalmic
surgical devices and instruments. Bausch + Lomb develops,
manufactures and markets one of the most comprehensive product
portfolios in our industry, which is available in more than 100
countries.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Forward-looking Statements
This news release may contain
forward-looking statements which may generally be identified by the
use of the words "anticipates," "expects," "intends," "plans,"
"should," "could," "would," "may," "will," "believes," "estimates,"
"potential," "target," or "continue" and variations or similar
expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties discussed in the Company's most recent
annual or quarterly report and detailed from time to time in
Valeant's other filings with the Securities and Exchange Commission
and the Canadian Securities Administrators, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of
the date hereof. Valeant undertakes no obligation to update any of
these forward-looking statements to reflect events or circumstances
after the date of this news release or to reflect actual outcomes,
unless required by law.
*Data obtained in bench study
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-receives-ce-mark-from-the-european-commission-for-the-stellaris-elite-vision-enhancement-system-including-the-vitesse-vitrectomy-system-300578252.html
SOURCE Valeant Pharmaceuticals International, Inc.